INVITATION


Dear Colleagues,


Turkish and British Associations for the Study of Liver (TASL-BASL) are pleased to announce a digital monothematic conference, “Drug-induced Liver Injury: Unresolved questions and unmet needs” on March 12-13, 2021. We hope that the programme will be a timely and welcome opportunity to reflect upon an area of critical importance for clinicians, researchers, scientists, pharma and other health care professionals.


Drugs and herbs are a common aetiology underlying acute liver injury. The number, variety and mechanism of action of drugs in use continues to expand. Along with this, interest and importance of drug-induced liver injury (DILI) has grown. Dissemination of knowledge related to DILI and a shared understanding is crucial to improve its diagnosis and safety of medications.


On behalf of TASL and BASL, we welcome you to join experts from Turkey and the United Kingdom in this event where we aim to appraise recent advances and emerging context in the field to identify priorities for future collaboration. We are excited to have this opportunity to create a partnership between TASL and BASL as well as to share the cutting-edge information with regards to DILI.


We look forward to seeing you all,





Prof. Guruprasad Aithal
President, BASL

Prof. Ramazan Idilman
President, TASL





    BASL Organizer
    Guruprasad Aithal

    TASL Organizer
    Fulya Gunsar

Scientific Secretariat

    Cemal Nuri Erçin
    Mujdat Zeybel
    Gupse Adalı



MAIN TOPICS

Session 1: Hepatotoxicity: Epidemiology and pathogenesis

  • Epidemiology – Pro- Euro- DILI network registry
  • TASL-Hepatotoxicity Database
  • Host and drug dependant risk factors for hepatotoxicity
  • Mechanisms of injury and immune-mediated reactions
  • Pharmacogenomics and DILI

Session 2: Clinical manifestations

  • Clinical presentation and patterns of DILI
  • Oral presentation
  • Drug-induced autoimmune hepatitis
  • Herbal and supplement-induced liver injury (HILI/SILI)

Session 3: The other presentations of hepatotoxicity

  • Acute fatty liver and drug-associated fatty liver disease(with case)
  • Liver toxicity due to treatments for COVİD(with case)
  • Check point inhibitor induced liver injury (CHILI)

Session 4: Toxic hepatitis and drug-drug interaction during chronic viral hepatitis

  • Toxic hepatitis and drug-drug interaction during HBV treatment
  • Toxic hepatitis and drug-drug interaction during HCV treatment in the era of DAA

Session 5: Causality assessment and diagnosis of DILI

  • Laboratory workup and imaging, Liver biopsy: when and whom?
  • Causality assessment methods and diagnosis
  • Liver histopathology

Session 6: Oral presentations of Selected Posters


Session 7: Severity and Prognosis of DILI

  • What is coming as new biomarkers for DILI?
  • Severity assessment and natural history chronic DILI
  • Re-challenge, recurrent DILI (with case)
  • Oral presentation

Session 8: Management in severe cases

  • General measures and specific therapies
  • Difficult decisions in management of severe DILI
  • Controversies in severe DILI: From EASL guideline to clinical practice

Session 9: Drug-induced acute liver failure

  • Mushroom poisoning and acute liver failure (with case)
  • Management of drug-induced ALF
  • Living donor liver transplant in drug-induced ALF
  • Future for DILI: Unresolved questions and unmet needs





SCIENTIFIC PROGRAM


12th of March 2021 Friday
13:15 - 13:30 Opening
Guruprasad Aithal, Ramazan Idilman, Fulya Günşar
Session - 1: Hepatotoxicity: Epidemiology and Pathogenesis
Chairs: Ramazan Idilman, Marsha Morgan
13:30 - 13:50
Epidemiology – Pro- Euro- DILI network registry
Jane Grove
13:50 - 14:10
TASL-Hepatotoxicity Database
Mujdat Zeybel
14:10 - 14:30
Host and drug dependant risk factors for hepatotoxicity
Cemal Nuri Ercin
14:30 - 14:50
Mechanisms of injury and immune-mediated reactions
Ye Htun Oo
14:50 - 15:10
Pharmacogenomics and DILI
Guruprasad Aithal
15:10 - 15:30
Discussion
15:30 - 15:40 BREAK
Session - 2: Clinical manifestations
Chairs: Guruprasad Aithal, Cihan Yurdaydin
15:40 - 16.00
Clinical presentation and patterns of DILI
William Griffiths
16:00 - 16:20
Oral presentation ( Case1: Ilker Turan - Case 2: Edmond Atalla: Dilemmas in DILI
16:20 - 16: 40
Drug-induced autoimmune hepatitis
Fulya Gunsar
16:40 - 17:00
Herbal and supplement-induced liver injury (HILI/SILI)
Marsha Morgan
17:00 - 17:20
Discussion
17:20 - 17:30 BREAK
Session - 3: The other presentations of hepatotoxicity
Chairs: Halis Şimşek , Mesut Akarsu
17:30 - 17:50
Acute fatty liver and drug-associated fatty liver disease(with case)
Yusuf Yilmaz
17:50 - 18:10
Liver toxicity due to treatments for COVİD (with case)
Yasemin Balaban
18:10 - 18:30
Check point inhibitor induced liver injury (CHILI)
Arjuna Singanayagam
18:30 - 18:50
Discussion
13th of March 2021 Saturday
Session - 4: Toxic hepatitis and drug reactions during chronic viral hepatitis
Chairs: Stephen Ryder, Sabahattin Kaymakoğlu
11:00 - 11:20
İmmunosupressive drugs induced HBV flares
Gupse Adalı
11:20 - 11:40
Liver Toxicity and drug-drug interaction during HCV treatment in the era of DAA:
Stephen Ryder
11:40 - 11:50
Discussion
Session - 5: Causality assessment and diagnosis of DILI
Chairs: Ye Htun Oo, Murat Harputluoğlu
11:50 - 12:10
Laboratory workup and imaging, Liver biopsy: when and whom? (with case)
Bülent Degertekin
12:10 - 12:30
Causality assessment methods and diagnosis
Marsha Morgan
12:30 - 12:50
Liver histopathology
Philip Kaye
12:50 - 13:10
Discussion
13:10 - 13:20
BREAK
Session - 6
13:20 - 13:50
Oral presentations of Selected Posters
Chairs: Tamir Rashid, Meral Akdoğan Kayhan
13.50 - 14:30
Satellite Symposium
VEMLIDY—For the Flow of Life with Chronic Hepatitis B
Monitoring Chronic Hep B patients during the pandemic to prevent drug toxicities
Chair: Prof. Dr. Sabahattin Kaymakoğlu
Speaker: Prof. Dr. Yusuf Yilmaz
Session - 7: Severity and Prognosis of DILI
Chairs: John Dillon, Ulus Akarca
14:30 - 14:50
What is coming as new biomarkers for DILI?
James Dear
14:50 - 15:10
Severity assessment and natural history chronic DILI
Murat Kıyıcı
15:10 - 15.30
Re-challenge, recurrent DILI
Nurdan Tözün
15:30 - 15:50
Oral presentation (Case 1 during Covid teratment)
Fatih Güzelbulut
15:50 - 16:10
Discussion
16:10 - 16:20 BREAK
Session - 8: Management in severe cases
Chairs: Osman Ozdogan, Mehmet Demir
16:20 - 16:40
General measures and specific therapies
Suna Yapalı
16:40 - 17:00
Difficult decisions in management of severe DILI (with case)
Hale Gokcan
17:00 - 17:20
Discussion
Session - 9: Drug-induced acute liver failure
Chairs: Zeki Karasu , Rebecca Jones
17:20 - 17:40
Mushroom poisoning and acute liver failure (with case)
Gökhan Kabacam
17:40 - 18:00
Management of drug-induced ALF
Adrian Reuben
18:00 - 18:20
Living donor liver transplant in drug-induced ALF : Turkish Chapter
Murat Akyıldız
18:20 - 18:40
Future for DILI: Unresolved questions and unmet needs
Guruprasad Aithal
18:40 - 19:00
Discussion
19:00 - 19:10
Closing remarks
Fulya Günşar, Guruprasad Aithal




ABSTRACT


ABSTRACTS

All abstracts should be submitted electronically via the abstractModule submission system. The abstracts not submitted via the abstract system but via e-mail and regular post shall not be accepted. The abstracts submitted online shall be published without any correction; therefore the authors should be careful about spelling mistakes.

Abstract Module
Abstract Submission Deadline 1 March 2021

Guidelines for Submission

  1. The abstracts shall be submitted only via the online abstract system.
  2. All abstracts should be written and presented in English.
  3. Names of the authors should not include their academic titles.
  4. The names should be written with only the first letter in capital and the rest in small letters and without abbreviation.
  5. Name and address of the institution, in which the author is employed, should be stated.
  6. Only the first letter of the abstract title should be in capital letters. (Abbreviations excluded.)
  7. In case abbreviation is used in the abstract, the abbreviation should be explained in parenthesis.
  8. The purpose of the paper and the methods applied should be explained in brief, the findings should be summarized together with sufficient statistical details and the conclusion should be stated within the framework of the findings presented.
  9. Abstract should be organized in a way to include the titles of objective, materials and methods, results and conclusions.
  10. The abstract length should not exceed 3000 characters excluding the abstract title, name and surname of the author.

Important Notices

  • If you will use the online abstract module for the first time, select the “New User” link and register to the system.
  • The explanations at the page after the registration procedure will guide you. Please read the messages and explanations carefully.
  • The abstracts submitted via internet shall be published without any corrections; therefore the authors should be careful about spelling mistakes.
  • Please keep the confirmation mail sent to your e-mail address following the abstract submission.
  • You can track the evaluation process of your abstract over the system by using your e-mail and password.
  • For technical assistance or questions during abstract submission contact Minduce IT Solutions Ltd. by emailing support@abstractmodule.com or calling phone: +90 216 410 44 14, 9:00 a.m. – 6:00 p.m. (EET), Monday-Friday.

Abstract Evaluation:

All abstracts and proceedings will be blind reviewed by the Scientific Committee. In order to have an accepted abstract being programmed by the scientific committee, congress registration for the presenting author is compulsory. An acceptance letter concerning the abstract evaluation result will be e-mailed to the author.



REGISTRATION



Before February 1, 2021
After February 1, 2021
Registration
3.000 TL
3.500 TL
    All registration fees excluding VAT.
    Registration fees includes the following services;
  • Participation to the scientific activities


ORGANIZATION SECRETARIAT

   D Event Turizm Organizasyon Hizmetleri Ltd. Şti.
   +90 312 438 10 39
   www.devent.com.tr - info@devent.com.tr

SCIENTIFIC SECRETARIAT